Short answer
Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter ended June 30, 2026 results announced August 6, 2026.
Definium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 results announced August 6, 2026
- Conference call covering financial results and recent corporate highlights
- Detailed financial figures and management commentary provided in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 Emerge met all efficacy endpoints in MDD, with Week 6 placebo-adjusted MADRS improvement of 8.1 points, Cohen’s d 0.83, p<0.0001
- DT120 ODT showed 7.3-point placebo-adjusted MADRS improvement at Week 12, with no serious adverse events or suicidality signal
- GAD catalysts approach: Voyage topline results anticipated week of August 10, 2026, and Panorama results anticipated September 2026
- Cash, equivalents and investments reached approximately $1.1B, including $757.9M net offering proceeds, supporting operations into 2030
- Net loss widened to $159.0M, driven by an $86.2M non-cash warrant-liability increase and higher R&D and G&A spending
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Definium Therapeutics, Inc. 8-K filings
Get the next DFTX 8-K as it lands
Follow DFTX for push alerts, or ask the research agent what this filing means.